FY2025 EPS Estimates for Bruker Decreased by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR) – Equities research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for shares of Bruker in a report released on Wednesday, May 7th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $2.46 per share for the year, down from their previous forecast of $2.55. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q2 2026 earnings at $0.58 EPS, FY2026 earnings at $2.88 EPS and FY2027 earnings at $3.35 EPS.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The company had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. During the same period in the previous year, the business earned $0.53 earnings per share. Bruker’s quarterly revenue was up 11.0% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group dropped their price target on Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Thursday, May 8th. Barclays decreased their target price on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 7th. Stifel Nicolaus lowered their price objective on Bruker from $57.00 to $48.00 and set a “hold” rating for the company in a research report on Thursday, May 8th. Finally, UBS Group reduced their target price on Bruker from $57.00 to $45.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bruker currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.10.

Bruker Stock Down 3.8%

Shares of NASDAQ BRKR opened at $38.74 on Monday. The firm’s 50-day moving average is $40.94 and its two-hundred day moving average is $50.89. The company has a market capitalization of $5.87 billion, a PE ratio of 50.97, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. Bruker has a 12-month low of $34.10 and a 12-month high of $79.78. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.52%. The ex-dividend date was Monday, March 17th. Bruker’s dividend payout ratio (DPR) is 38.46%.

Institutional Trading of Bruker

Large investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock worth $779,000 after acquiring an additional 177 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 196 shares in the last quarter. Insigneo Advisory Services LLC boosted its stake in shares of Bruker by 4.7% during the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company’s stock valued at $286,000 after buying an additional 218 shares during the last quarter. Arizona State Retirement System grew its position in shares of Bruker by 0.7% during the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock worth $1,801,000 after buying an additional 222 shares in the last quarter. Finally, CIBC Asset Management Inc increased its position in shares of Bruker by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock worth $248,000 after purchasing an additional 223 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.